Streetbeat News

BCTX

BriaCell Therapeutics Corp.

https://www.briacell.com

Industry

Biotechnology

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Open

0.39

Mkt cap

17M

Volume

178K

High

0.40

P/E Ratio

-0.43

52-wk high

4.37

Low

0.37

Div yield

N/A

52-wk low

0.37

BriaCell is progressing with its Phase 3 clinical trial for Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer. The trial is active at 35 sites, with the primary endpoint being overall survival. Interim data analysis is planned at 144 events, potentially leading to full approval and marketing authorization. Patient enrollment is expected to complete by mid-2025, and no serious adverse events have been reported.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:56 am

HC Wainwright & Co. has reiterated its Buy rating for BriaCell Therapeutics, maintaining a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:02 am

Shares of JD.com and other US-listed Chinese stocks rose in pre-market trading due to recent stimulus measures and China National Day celebrations. JD.com shares increased by 10.6%. Other notable gainers include Agora, MMTec, and Fangdd Network Group. Meanwhile, AgEagle Aerial Systems and Akoustis Technologies were among the pre-market losers.

Portfolio Pulse from Avi Kapoor

October 02, 2024 | 10:59 am

BriaCell Therapeutics shares fell following the announcement of a $5.13 million offering of shares and warrants priced at $0.975 per unit.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:26 pm

BriaCell Therapeutics has announced a $5 million offering consisting of 5.13 million shares and warrants, priced at $0.975 per unit.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 6:07 pm

HC Wainwright & Co. has maintained a Buy rating on BriaCell Therapeutics but lowered the price target from $18 to $15.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 10:32 am

BriaCell Therapeutics shares rose following the US FDA's authorization of an expanded access policy for metastatic breast cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:06 pm

BriaCell Therapeutics has received US FDA authorization for an Expanded Access Policy (EAP) to provide its treatment to metastatic breast cancer patients. This development could enhance the company's market presence and patient reach.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 11:51 am

The Nasdaq Composite surged over 200 points, driven by a rise in information technology shares. PureCycle Technologies, BriaCell Therapeutics, and Liquidia Corporation saw significant stock price increases due to positive company announcements. Conversely, Telesis Bio, Rentokil Initial, and Torrid Holdings experienced sharp declines following negative news. U.S. crude oil inventories rose slightly less than expected.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 6:30 pm

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for BriaCell Therapeutics, maintaining a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 5:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.